122 related articles for article (PubMed ID: 6380408)
1. N alpha-Malto-glucagon and N alpha-malto, S-methyl methionine27-glucagon: preparation and characterization of two partial agonists.
Coolican SA; Gurd RS
Arch Biochem Biophys; 1984 Aug; 232(2):450-7. PubMed ID: 6380408
[TBL] [Abstract][Full Text] [Related]
2. Semisynthetic derivatives of glucagon: (des-His1)N epsilon-acetimidoglucagon and N alpha-Biotinyl-N epsilon-acetimidoglucagon.
Flanders KC; Mar DH; Folz RJ; England RD; Coolican SA; Harris DE; Floyd AD; Gurd RS
Biochemistry; 1982 Aug; 21(18):4244-51. PubMed ID: 7126542
[TBL] [Abstract][Full Text] [Related]
3. Semisynthetic D-His1,N epsilon-acetimidoglucagon: structure-function relationships.
Mahrenholz AM; Flanders KC; Hoosein NM; Gurd FR; Gurd RS
Arch Biochem Biophys; 1987 Sep; 257(2):379-86. PubMed ID: 2821912
[TBL] [Abstract][Full Text] [Related]
4. Effect of specific trinitrophenylation of the lysine epsilon amino group of glucagon on receptor binding and adenylate cyclase activation.
Liepnieks JJ; Epand RM
Arch Biochem Biophys; 1983 Aug; 225(1):102-9. PubMed ID: 6311099
[TBL] [Abstract][Full Text] [Related]
5. Properties of amidinated glucagons.
Wright DE; Rodbell M
Eur J Biochem; 1980 Oct; 111(1):11-6. PubMed ID: 7439177
[TBL] [Abstract][Full Text] [Related]
6. Preparation of 2-thioltryptophan-glucagon and (tryptophan-S-glucagon)2. Differences in binding to the glucagon receptor in the hepatic adenylate cyclase system.
Wright DE; Rodbell M
J Biol Chem; 1980 Nov; 255(22):10884-7. PubMed ID: 7430160
[TBL] [Abstract][Full Text] [Related]
7. The role of nonspecific hydrophobic interactions in the biological activity of N epsilon-acyl derivatives of glucagon. Studies of conformation, receptor binding, and adenylate cyclase activation.
Carrey EA; Epand RM
J Biol Chem; 1982 Sep; 257(18):10624-30. PubMed ID: 6286664
[TBL] [Abstract][Full Text] [Related]
8. Receptor binding and adenylate cyclase activities of glucagon analogues modified in the N-terminal region.
McKee RL; Pelton JT; Trivedi D; Johnson DG; Coy DH; Sueiras-Diaz J; Hruby VJ
Biochemistry; 1986 Apr; 25(7):1650-6. PubMed ID: 3011069
[TBL] [Abstract][Full Text] [Related]
9. Differential acid stabilities of citraconylated amino groups of glucagon. Preparation of N alpha-citraconyl glucagon and evaluation of its biological properties.
Liepnieks JJ; Epand RM
Biochim Biophys Acta; 1982 Oct; 707(2):171-7. PubMed ID: 6291617
[TBL] [Abstract][Full Text] [Related]
10. Acetylglucagon: preparation and characterization.
Desbuguois B
Eur J Biochem; 1975 Dec; 60(2):335-47. PubMed ID: 1270
[TBL] [Abstract][Full Text] [Related]
11. Glucagon carboxyl-terminal derivatives: preparation, purification, and characterization.
England RD; Jones BN; Flanders KC; Coolican SA; Rothgeb TM; Gurd RS
Biochemistry; 1982 Mar; 21(5):940-50. PubMed ID: 7074063
[TBL] [Abstract][Full Text] [Related]
12. Methylation of glucagon, characterization of the sulfonium derivative, and regeneration of the native covalent structure.
Rothgeb TM; Jones BN; Hayes DF; Gurd RS
Biochemistry; 1977 Dec; 16(26):5813-8. PubMed ID: 588556
[TBL] [Abstract][Full Text] [Related]
13. Structural requirements for glucagon receptor binding and activation of adenylate cyclase in liver. Study of chemically modified forms of the hormone, including N alpha-trinitrophenyl glucagon, an antagonist.
Epand RM; Rosselin G; Hoa DH; Cote TE; Laburthe M
J Biol Chem; 1981 Feb; 256(3):1128-32. PubMed ID: 6256384
[TBL] [Abstract][Full Text] [Related]
14. Semisynthetic derivatives of glucagon. The contribution of histidine-1 to hormone conformation and activity.
Flanders KC; Horwitz EM; Gurd RS
J Biol Chem; 1984 Jun; 259(11):7031-7. PubMed ID: 6547139
[TBL] [Abstract][Full Text] [Related]
15. Receptor occupancy and adenylate cyclase activation in rat liver and heart membranes by 10 glucagon analogs modified in position 2,3, 4, 25, 27 and/or 29.
Robberect P; Damien C; Moroder L; Coy DH; Wünsch E; Christophe J
Regul Pept; 1988 May; 21(1-2):117-28. PubMed ID: 2839870
[TBL] [Abstract][Full Text] [Related]
16. Structure-conformation-activity studies of glucagon and semi-synthetic glucagon analogs.
Hruby VJ
Mol Cell Biochem; 1982 Apr; 44(1):49-64. PubMed ID: 6283336
[TBL] [Abstract][Full Text] [Related]
17. Preparation and properties of glucagon analogs prepared by semi-synthesis from CNBr-glucagon.
Wright DE; Hruby VJ; Rodbell M
Biochim Biophys Acta; 1980 Aug; 631(1):49-58. PubMed ID: 6249392
[TBL] [Abstract][Full Text] [Related]
18. Glucagon antagonists: contribution to binding and activity of the amino-terminal sequence 1-5, position 12, and the putative alpha-helical segment 19-27.
Unson CG; Gurzenda EM; Iwasa K; Merrifield RB
J Biol Chem; 1989 Jan; 264(2):789-94. PubMed ID: 2536024
[TBL] [Abstract][Full Text] [Related]
19. Re-evaluation of glucagon1-6: the N-terminal hexapeptide of glucagon is not biologically active in the hepatic adenylate cyclase system.
Pelton JT; Trivedi D; Hruby VJ
Life Sci; 1983 Sep; 33(13):1307-14. PubMed ID: 6888179
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of seven synthetic glucagon analogs, modified in position 1, 2 and/or 12, on liver and heart adenylate cyclase from rat.
Robberecht P; Waelbroeck M; Camus JC; De Neef P; Coy DH; Christophe J
Peptides; 1986; 7 Suppl 1():109-12. PubMed ID: 3018688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
